Mature results favor pembrolizumab as second-line treatment for bladder cancer

(European Society for Medical Oncology) Mature results from the KEYNOTE-045 trial to be presented today at the ESMO 2017 Congress in Madrid have confirmed significantly longer survival in patients with advanced urothelial cancer who receive the checkpoint inhibitor pembrolizumab after initial chemotherapy, compared to an alternative chemotherapy regimen.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news